$HRTX, Analyst Activity – Needham & Company
Post# of 23071
(Total Views: 49)
Posted On: 02/27/2017 9:53:53 AM
$HRTX,
Analyst Activity – Needham & Company LLC Initiates Coverage On Heron Therapeutics (NASDAQ:HRTX) With a Buy
By
ME Staff -
February 27, 2017
18
Share on Facebook
Tweet on Twitter
Analyst Ratings For Heron Therapeutics (NASDAQ:HRTX)
Trade Free For 60 Days when you Open a New OptionsHouse Account
Today, Needham & Company LLC initiated coverage on Heron Therapeutics (NASDAQ:HRTX) with a Buy with a price target of $28.00.
There are 10 buy ratings on the stock.
The current consensus rating on Heron Therapeutics (NASDAQ:HRTX) is Buy (Score: 3.00) with a consensus target price of $36.67 per share, a potential 163.79% upside.
Some recent analyst ratings include
2/27/2017-Needham & Company LLC initiated coverage with a Buy rating.
1/6/2017-Cowen and Company Reiterated Rating of Buy.
11/9/2016-JMP Securities Reiterated Rating of Buy.
10/26/2016-Aegis initiated coverage with a Buy rating.
Dividend information for Heron Therapeutics (NASDAQ:HRTX)
.
On 1/19/2017 Kevin C Tang, Director Buy, 2,459,016 $12.20 with an average share price of $29,999,995.20 View SEC Filing 8/10/2016 per share and the total transaction amounting to Robert Rosen.
On 4/21/2016 Robert Rosen, President Sell, 200,000 $23.23 with an average share price of $4,646,000.00 View SEC Filing 6/10/2015 per share and the total transaction amounting to Kevin C Tang.
On 6/2/2015 Kevin C Tang, Director Buy, 150,000 $20.62 with an average share price of $3,093,000.00 View SEC Filing 6/1/2015 per share and the total transaction amounting to Kimberly Manhard.
On 6/25/2014 Barry D Quart, CEO Buy, 10,000 $11.75 with an average share price of $117,500.00 View SEC Filing 6/25/2014 per share and the total transaction amounting to Kevin C Tang.
About Heron Therapeutics (NASDAQ:HRTX)
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company’s SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
Recent Trading Activity for Heron Therapeutics (NASDAQ:HRTX)
Shares of Heron Therapeutics closed the previous trading session at 13.90 0.00 0.00% with 1,649,416 shares trading hands.
Analyst Activity – Needham & Company LLC Initiates Coverage On Heron Therapeutics (NASDAQ:HRTX) With a Buy
By
ME Staff -
February 27, 2017
18
Share on Facebook
Tweet on Twitter
Analyst Ratings For Heron Therapeutics (NASDAQ:HRTX)
Trade Free For 60 Days when you Open a New OptionsHouse Account
Today, Needham & Company LLC initiated coverage on Heron Therapeutics (NASDAQ:HRTX) with a Buy with a price target of $28.00.
There are 10 buy ratings on the stock.
The current consensus rating on Heron Therapeutics (NASDAQ:HRTX) is Buy (Score: 3.00) with a consensus target price of $36.67 per share, a potential 163.79% upside.
Some recent analyst ratings include
2/27/2017-Needham & Company LLC initiated coverage with a Buy rating.
1/6/2017-Cowen and Company Reiterated Rating of Buy.
11/9/2016-JMP Securities Reiterated Rating of Buy.
10/26/2016-Aegis initiated coverage with a Buy rating.
Dividend information for Heron Therapeutics (NASDAQ:HRTX)
.
On 1/19/2017 Kevin C Tang, Director Buy, 2,459,016 $12.20 with an average share price of $29,999,995.20 View SEC Filing 8/10/2016 per share and the total transaction amounting to Robert Rosen.
On 4/21/2016 Robert Rosen, President Sell, 200,000 $23.23 with an average share price of $4,646,000.00 View SEC Filing 6/10/2015 per share and the total transaction amounting to Kevin C Tang.
On 6/2/2015 Kevin C Tang, Director Buy, 150,000 $20.62 with an average share price of $3,093,000.00 View SEC Filing 6/1/2015 per share and the total transaction amounting to Kimberly Manhard.
On 6/25/2014 Barry D Quart, CEO Buy, 10,000 $11.75 with an average share price of $117,500.00 View SEC Filing 6/25/2014 per share and the total transaction amounting to Kevin C Tang.
About Heron Therapeutics (NASDAQ:HRTX)
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company’s SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
Recent Trading Activity for Heron Therapeutics (NASDAQ:HRTX)
Shares of Heron Therapeutics closed the previous trading session at 13.90 0.00 0.00% with 1,649,416 shares trading hands.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'